Clinical Trials Contact

About this Clinical Trial

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Your Message Will Go To

Team Phase 1

Phase1Team@stanfordhealthcare.org


All fields are required. *

Preferred contact method*

To:

Team Phase 1

Phase1Team@stanfordhealthcare.org



Go Back To The Trial

We were not able to send your contact info at this time.

Go Back To The Trial

©2022 Stanford Medicine